`
`FiercePharma
`
`Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains - FiercePharma
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Daily Pharma Industry Newsletter Every business day, FiercePharma updates pharmaceutical executives on the latest Pharma industry news
`and deals. Stay up to date on:
`Pharma Company News ∣ Generic Drug Companies ∣ Pharmaceutical Marketing & Sales ∣ FDA Regulations & Warnings ∣ Phase IV Clinical Trials
`Click here to see a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE
`
`Why is Novartis' Copaxone copy lagging? It's all
`about coverage, analyst explains
`September 11, 2015 | By Carly Helfand
`
`Typically, the first generics for
`blockbuster meds get off to a running
`start. Not so with Novartis' ($NVS)
`generic of Teva's ($TEVA) multiple
`sclerosis standout Copaxone, though
`and Bernstein analyst Ronny Gal thinks
`he can explain why.
`
`The Swiss pharma giant's knockoff, dubbed Glatopa, right now has market share
`of only about 20%as opposed to the roughly 50% some industrywatchers say
`it's capable of snagging. And that could be because coverage of the copy is
`"considerably behind that of Copaxone," he wrote in a Friday note to clients.
`
`Copaxone reaches the "best available coverage" tier for 59% of covered lives,
`he pointed out, while Glatopa can only boast that level for 31%. Many payers
`have kept Teva's original as either preferred or equally accessible thanks to
`discounting, he noted, and on top of that, Glatopalikely thanks to its high price
`is treated by many plans as a branded product.
`
`SHARE
`
`Tweet
`
`88
`
`Share
`
`34
`
`Like
`
`0
`
`TOOLS
`
`[Webinar]Improving Commercial Content Compliance &
`Productivity: Results from New Industry Survey
`
`Comment
`
`DATE: JANUARY 21ST | 12PM ET / 9AM PT
`DISCOVER NEW TRENDS AND STRATEGIES TO IMPROVE COMPLIANCE AND
`MARKETING PRODUCTIVITY. SEE HOW YOUR ORGANIZATION COMPARES. REGISTER NOW!
`
`
`Sign up for our FREE newsletter for more news like this sent to your inbox!
`
`FOLLOW US
`
`J O I N 1 5 0 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`FiercePharma is the pharma industry's daily monitor,
`with a special focus on pharmaceutical company news
`and the market development of FDA approved
`products. Join thousands of pharma industry leaders
`who get FiercePharma via daily email. Sign up today!
`
`EMAIL ADDRESS
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`The biosimilars are coming. But how long will it be
`till they can make their mark?
`Think we've seen the last of pharma's M&A tidal
`wave? Think again
`What's the calendar bringing biopharma next year?
`Our top 5 ideas
`Brace yourselves: The drug pricing brouhaha isn't
`dying down
`Shire inches closer to Baxalta buy with cash
`sweetened bid
`
`THE LIBRARY: WEBINAR
`Optimizing Your Clinical Supply Chain Strategy
`for AsiaPacific Studies
`
`| THURSDAY, JANUARY 28, 2016 | 10AM
`ET / 7AM PT | PRESENTED BY:
`CATALENT
`
`Contact
`Author
`
`Reprint
`
`In this webinar we will explore how to leverage
`the major clinical supply centers of China,
`Singapore and Japan to support clinical trials
`within the AsiaPacific region for both local and
`global study sponsors. We will explore clinical
`packaging, logistics and import/export
`Novartis' Sandoz unit, though, appears to be taking that tack deliberately. It "can
`considerations that should be taken into
`always lower its price and capture share," Gal noted, but right now, it "appears to
`account when developing a clinical supply
`be interested in building share cautiously in order to protect market price." The
`strategy and why there is no substitute for on
`http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11
`
`"It appears that the lower penetration is, for the most part, factual and simply
`reflects current formulary status coverage," Gal wrote. Teva is offering more
`discount to payers, and those payers are preferring its brand over equally or
`slightly more expensive Glatopa."
`
`1/3
`
`MYLAN PHARMS. INC. EXHIBIT 1105 PAGE 1
`
`
`
`12/28/2015
`
`Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains - FiercePharma
`way he sees it, Sandoz is holding the reins, and as it gradually brings its price
`the ground local expertise. Reserve Your Spot
`Today!
`down, "share will shift," he wrote.
`
`MORE ITEMS
`
`LATEST COMMENTARY
`
`What's the calendar bringing biopharma next year?
`Our top 5 ideas
`The most popular FiercePharma stories of 2015
`Does new scrutiny threaten pharma's specialty
`pharmacy strategy?
`Pfizer responds to FiercePharma
`Jardiance and its CV data? They're no knockout
`punch for stalwart Januvia, Merck says
`
`EVENTS
`
`Data Science for Pharma 2016
`Jan 2628 — London, UK — Sponsored by:
`Hanson Wade
`
`The Pharma CI Europe Conference &
`Exhibition
`February 1819, 2016 — Paris, France
`
`PCC 2016 – CBI’s 13th Pharma Compliance
`Congress
`January 2627, 2016 — Washington, DC
`MORE EVENTS
`
`
`
`There's another question on the minds of industrywatchers, though, and that's
`how Glatopa will affect payer coverage on Teva's nextgen version of Copaxone.
`In July, Gal predicted Glatopa's presence would lead payers to restrict the
`newcomer version as they work to manage costs. And that could be bad news
`for Teva, which managed to convert patients over to the longacting version at a
`rate that had analysts impressed.
`
`Special Report: The top 10 bestselling multiple sclerosis drugs of 2013
`Copaxone Tecfidera | Top 15 drug launch superstars Tecfidera Biogen
`
`Related Articles:
`Novartis off to scorching start with Copaxone generic Glatopa
`Roche's MS hopeful will amp up payer pricing pressure, analyst says
`U.S. court nixes Teva's Copaxone patentagain
`Teva's years of Copaxone brandbuilding pay off in new formula's launch
`What price MS therapy? Thanks to price hikes, $50Kplus, even for decadesold
`meds
`Bad news, TevaSandoz has an FDA nod for generic Copaxone. But when will
`it launch?
`Can Teva persuade payers that pricey longacting Copaxone beats cheap
`generics?
`
`EMAIL ADDRESS
`
`Filed Under Novartis
`
`COMMENTS
`
` SPONSORED
`
`HISTORY IN ORBIT
`50's Classic Adult Pin-Ups. It Was Sexier Than You Thought
`Modeling has changed dramatically since the 50's. Check out what it
`used to be like and the actual girls behind the pin-ups.
`
`Learn More
`
`0 Comments
`
`FiercePharma
`
` Recommend
`
`
`
` Share⤤
`
`Start the discussion…
`
`Be the first to comment.
`
`Subscribe
`
`✉
`
`d
`
`Add Disqus to your site Add Disqus Add
`
`Privacy
`
`
`
` Login
`
`1
`Sort by Best
`
`PRESS RELEASES
`Novartis announces NEJM publication of two major trials showing
`significant efficacy of Cosentyx in ankylosing spondylitis patients
`Aquinnah Pharmaceuticals Receives $5 Million Investment from Takeda
`http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11
`
`FEATURED JOBS
`> Need a job? Need to hire? Visit our jobs site.
`
`2/3
`
`MYLAN PHARMS. INC. EXHIBIT 1105 PAGE 2
`
`
`
`Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains - FiercePharma
`12/28/2015
`Pharmaceuticals To Advance New Therapies in ALS
`Huya Bioscience International Announces Orphan Drug Designation For
`HBI8000 In Japan
`CSL Behring Submits New Drug Application to Japan';s
`Pharmaceuticals and Medical Devices Agency for rIXFP for Hemophilia
`B Patients
`Porsolt Expands Its in Vitro Drug Discovery Service Capabilities With the
`Acquisition of Fluofarma
`More Press Releases
`
`A publication of
`
`FiercePharma is the pharma
`industry's daily monitor, with
`a special focus on
`pharmaceutical company
`news and the market
`development of FDA
`approved products. Join
`150,000+ pharma industry
`leaders who get
`FiercePharma via daily
`email. Click here to get your
`free weekly email briefing
`today!
`
`The FierceMarkets Network:
`Telecom
`FierceCable
`FierceDeveloper
`FierceWireless:Europe
`FierceWirelessTech
`FierceOnlineVideo
`FierceTelecom
`FierceWireless
`FierceInstaller
`
`Marketing & Retail
`FierceCMO
`FierceMobileMarketer
`FierceRetail
`FierceRetailIT
`FierceMobileRetail
`
`Healthcare
`FierceEMR
`FierceHealthcare
`FierceHealthFinance
`FierceHealthIT
`FierceHealthPayer
`FierceHealthPayerAntiFraud
`FierceMobileHealthcare
`FiercePracticeManagement
`Hospital Impact
`
`Government
`FierceGovernment
`FierceGovernmentIT
`FierceHomelandSecurity
`FierceMobileGovernment
`FierceCities
`FierceGovHealthIT
`
`Life Sciences
`FierceBiotechResearch
`FierceBiotech
`FierceBiotechIT
`FierceCRO
`FierceDrugDelivery
`FierceMedicalDevices
`FiercePharma
`FiercePharmaAsia
`FiercePharmaManufacturing
`FiercePharmaMarketing
`FierceVaccines
`FierceAnimalHealth
`
`Enterprise IT
`FierceBigData
`FierceCIO
`FierceContentManagement
`FierceDevOps
`FierceEnterpriseCommunications
`FierceITSecurity
`FierceMobileIT
`
`Energy
`FierceEnergy
`SmartGridNews
`FierceWater
`
`Finance
`FierceCFO
`FierceFinanceIT
`
`Home Subscribe Manage Newsletter Subscriptions Advertise Contact Mobile Apps RSS Privacy Editors List in Marketplace
`© 2015 FierceMarkets, a division of Questex, LLC. All rights reserved.
`
`http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11
`
`3/3
`
`MYLAN PHARMS. INC. EXHIBIT 1105 PAGE 3